For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- LDP Taskforce Begins Social Security Debates towards Honebuto
March 3, 2023
- MHLW Unveils New List Prices for FY2023 Revision, Ad-Hoc PMP Raise for 143 Products
March 3, 2023
- Komeito Petitions Govt for Market Incentives for Meiji’s Novel Antibacterial
March 2, 2023
- LDP League to Compile Final Proposal for SaMD Reimbursement This Spring
March 2, 2023
- Shelf Life of Ronapreve, Xevudy Extended to 30 Months in Japan
March 1, 2023
- Japan Panel Backs Approval of 1st Nasal Flu Vaccine
February 28, 2023
- Pfizer’s Omicron-Adapted Jab for Ages 5-11 in Line for Japan Approval
February 28, 2023
- Nipro Pharma Told to Improve Biz over Violations Spanning 42 Products, Faked Records
February 27, 2023
- Japan Approves Precedex for Pediatric Use, Expands Labels for Nubeqa, Rinvoq, and More
February 27, 2023
- PMDA Reviewing 16 APIs for Paradoxical Drug Reaction
February 27, 2023
- Komeito Poised to Call for Govt Support on Meiji Pharma’s Nacubactam
February 27, 2023
- Japan Panel OKs Plan to Offer 2 Boosters for Elderly in FY2023; Program to Start from May
February 24, 2023
- Alexion’s Danicopan, Pfizer’s Elranatamab and 2 More APIs Get Orphan Tag
February 24, 2023
- Nipro Pharma Likely to Face Business Improvement Order over Violations
February 24, 2023
- MHLW Panel Maintains Caution against Xocova Use in Women Who Might Be Pregnant
February 22, 2023
- MOF to Work with Industry to Boost Drug Discovery, Minister Says on Trade Deficit
February 22, 2023
- MHLW to Launch SaMD Working Group to Compile Opinions by Summer
February 22, 2023
- Japan Eyes Two COVID Shots a Year for Elderly, High-Risk People
February 22, 2023
- Consider Special Characteristics of Patches If Govt Is to Revise LLP Pricing Rules: LDP League
February 21, 2023
- LDP Project Team Hears Report on Expert Panel Debate; Chair Voices Difficulty around Political Intervention
February 21, 2023
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…